Background And Overview: Oral melanomas vary in color and morphology and resemble myriad other reactive, benign, or malignant conditions. The authors describe a case report of a patient with a primary oral melanoma that presented as a nonspecific ulcer, which showed nodal metastasis during resection.
Case Description: A 64-year-old man who was examined by his periodontist to assess implant healing had a reddish-purple ulcer of the maxillary mucosa of 3 to 4 weeks duration. The implant was placed 19 weeks earlier in the mandible. The provisional diagnosis was that this ulcer was a traumatic or inflammatory lesion. The clinician biopsied the tissue at the 1-week follow-up appointment, which was identified as melanoma. The patient had a partial maxillectomy and ipsilateral neck dissection. Tissue examination showed nodal metastasis. Two months later, contralateral neck node metastasis was diagnosed and treated.
Conclusions And Practical Implications: In contrast to cutaneous melanoma, oral melanoma has a poor prognosis because of delayed diagnosis. Thorough oral examination at each dental visit may improve the outcome of this fatal condition.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.adaj.2016.10.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unraveling the controversy: exploring the link between sex hormones and skin cancers through a meta-analysis and systematic review.
Arch Dermatol Res
January 2025
Department of Plastic and Burn Surgery, West China Hospital, Sichuan University, No. 37, Guoxue Alley, Wuhou District, Chengdu, 610041, Sichuan Province, P. R. China.
Skin cancers continue to present unresolved challenges, particularly regarding the association with sex hormones, which remains a topic of controversy. A systematic review is currently warranted to address these issues. To analyze if sex hormones result in a higher incidence of skin cancers (cutaneous melanoma, basal cell carcinoma, squamous cell carcinoma).
View Article and Find Full Text PDFDiagnostic and Prognostic Challenges of Oral Melanoma in Dogs: A Literature Review and 2 Case Studies.
J Vet Dent
January 2025
Specialty Oral Pathology for Animals, Geneseo, IL, USA.
Oral melanoma is the most common maxillofacial malignancy in dogs. A unique characteristic of melanoma is its ability to mimic other oral tumors, which makes it one of the most challenging oral tumors to diagnose, especially since 30% to 40% of cases are amelanotic. This article presents 2 case reports of dogs with amelanotic oral melanoma that were both diagnostically challenging.
View Article and Find Full Text PDFOral Blue Nevus of the Lingual Gingiva: A Case Report.
Cureus
January 2025
College of Dentistry, King Saud University, Riyadh, SAU.
Oral melanocytic nevi (OMN) are rare benign tumors originating from melanocytes with an unclear pathogenesis. The current theory suggests that OMN originate from dormant dendritic melanocytes that become enclosed in the dermis during the embryonic migration of melanoblasts - the precursors of melanocytes - from the neural crest to the epidermis. OMN can be congenital or acquired, with acquired nevi being more common.
View Article and Find Full Text PDFProlonged Remission in Metastatic Ano-Rectal Malignant Melanoma With Single Agent Temozolomide.
Cancer Rep (Hoboken)
January 2025
Department of Medical Oncology, Hematology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
Introduction: With the use of immune checkpoint inhibitors (ICIs) and targeted therapies, the clinical outcomes of metastatic melanoma have drastically improved. The current scenario has reduced the use of chemotherapy as a first-line treatment. We report an interesting case of a patient with stage IV ano-rectal canal malignant melanoma with an exceptional response to single-agent temozolomide.
View Article and Find Full Text PDFDiscovery of FHD-286, a First-in-Class, Orally Bioavailable, Allosteric Dual Inhibitor of the Brahma Homologue (BRM) and Brahma-Related Gene 1 (BRG1) ATPase Activity for the Treatment of SWItch/Sucrose Non-Fermentable (SWI/SNF) Dependent Cancers.
J Med Chem
January 2025
Foghorn Therapeutics, 500 Technology Square, Suite 700, Cambridge, Massachusetts 02139, United States.
BRM (SMARCA2) and BRG1 (SMARCA4) are mutually exclusive ATPase subunits of the mSWI/SNF (BAF) chromatin remodeling complex. BAF is an attractive therapeutic target because of its role in transcription, and mutations in the subunits of BAF are common in cancer and neurological disorders. Herein, we report the discovery of compound () as a potent allosteric inhibitor of the dual ATPase subunits from a high-throughput screening hit with a BRM IC of ∼27 μM.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!